8:00
David S. Boyer, MD
Gene Therapy for Treatment of Wet Macular Degeneration

8:25
Thomas G. Chu, MD
Ergonomics in Medicine and Surgery

8:45
Firas M. Rahhal, MD
Treatment of Diabetic Retinopathy in 2021

9:10
Homayoun Tabandeh, MD
Macular Hole

9:30
Pouya N. Dayani, MD
Syphilitic Uveitis

9:50
David S. Liao, MD
Cell Based Therapies for Retinitis Pigmentosa

10:10
Break
Break / Exhibits

10:30
Alex C. Walsh, MD
Ophthalmic Manifestations of Covid-19

10:45
Dan D. Esmaili, MD
Vitreo-Macular Traction

11:05
Jeffrey J. Tan, MD
Update on Sutureless Sclera-Fixated IOL

11:30
Daniel Su, MD
Scleral Sutured IOL (with Goretex) & refractive outcomes

11:50
Ramsudha Narala, MD
Pigmented Lesions of Retina and Choroid

12:10
Richard H. Roe, MD
DRCR Protocol U - Adjunctive steroids for DME following Anti-VEGF therapy

12:30
Adjourn

By the end of the session the participant will be able to:

• Recognize symptoms related to diseases of the Retina, Macula and Vitreous
• Diagnose patients earlier and slow the vision loss process
• Discuss treatment options for these diseases with patients, including clinical trials and appropriate referrals
• Implement new strategies for on early prevention of diseases and increased quality of life with their patients
• Outline any variations in epidemiology, diagnosis or treatment by age, gender, ethnicity, language, culture or socioeconomic factors

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

See program materials.

David Boyer, MD has received financial compensation from:

Acucela Consultant
Adverum Biotech Consultant, Grant Res
Aerie Pharma Grant Rsearch
Aerpio Consultant, Grant Res
Alimera Sciences Consultant
Allegro Consultant
Allergan Consultant, Grant Res
Apellis Consultant, Grant Res
Bayer Consultant
Chengdu Kanghong Consultant, Grant Res

Clearside BiomedicalConsultant, Grant Res
Eyepoint Pharma Consultant
Gemini Therap Consultant
Genentech/ Roche Consultant, Grant Res
GrayBug Vision Consultant
IONIS Pharma Consultant
Kodiak Consultant, Grant Res
Neurotech Consultant
Novartis Consultant, Grant Res
ONL Therap Consultant
Opthea Consultant
Outlook Therap Consultant
Oxurion Consultant
Recens Medical Consultant, Grant Res
Regeneron Consultant, Grant Res
Regenxbio Consultant
Roche Consultant, Grant Res
Santen Consultant, Grant Res
Takeda Consultant

Thomas G. Chu, MD
Nothing to Disclose

Pouya Dayani, MD has received financial compensation from:

Novartis Speakers Bureau

Regeneron Speakers Bureau

Eyepoint Pharma Speakers Bureau

Daniel D. Esmaili, MD has received financial compensation from:

Regeneron Speakers Bureau

David S. Liao, MD
Nothing to Disclose

Ramsudha Narala, MD
Nothing to Disclose

Firas Rahhal, MD has received financial compensation from:

Alcon Advisor
Beaver-Visitec (BVI) Advisor
ReVana Therapeutics Consultant
Zeiss Advisor
Alpine Therapeutics Advisor
Outlook Therap Advisor
ExSight Ventures Stockholder

Richard H. Roe, MD has received financial compensation from:

Alcon Surgical Consultant

Daniel Su, MD
Nothing to Disclose

Homayoun Tabandeh, MD is a stockholder in: Alimera Sciences

Jeffrey J. Tan, MD
Nothing to Disclose

Alexander C. Walsh, MD is Employee/Director and Stockholder of Envision Diagnostics, Inc

Activity Planner, Maria Gutierrez, has Nothing to Disclose

Activity Reviewer,  Charles J. Turck, PharmD, has Nothing to Disclose

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 60% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

*Required to view Printable PDF Version